

Population mortality affects long-term followup of AlloHCT

April 3 2019



(HealthDay)—For older patients undergoing allogeneic hematopoietic



cell transplantation (alloHCT), a considerable part of total nonrelapse mortality (NRM) is attributable to population mortality, according to a study recently published in *Leukemia*.

Johannes Schetelig, M.D., from the Universitaetsklinikum Dresden in Germany, and colleagues examined the contribution of relapse-related, treatment-related, and population factors on late patient mortality after alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia. Data from 6,434 adults were retrospectively studied.

The researchers found that the probability of overall survival was 53 and 35 percent at two and 10 years after alloHCT, respectively. The probability of survival was 88 and 63 percent at five years from the two-year landmark for patients aged

Citation: Population mortality affects long-term follow-up of AlloHCT (2019, April 3) retrieved 26 June 2024 from

https://medicalxpress.com/news/2019-04-population-mortality-affects-long-term-follow-up.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.